Claims

- 1. A reagent for diagnosis and/or prognostic evaluation of carcinoma, which comprises an anti-P-LAP antibody as an active ingredient.
- 2. The reagent as claimed in Claim 1, wherein the carcinoma is gynecological carcinoma.
- 3. The reagent as claimed in Claim 2, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

10

20

- 4. The reagent as claimed in any one of Claims 1 to 3, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.
- 5. The reagent as claimed in any one of Claims 1 to 3, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.
 - 6. A method for determination of P-LAP which is a prognostic factor in carcinoma, which comprises
 - (a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody, and
 - (b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody.
- 7. The method as claimed in Claim 6, wherein the carcinoma is gynecological carcinoma.
 - 8. The method as claimed in Claim 7, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.
 - The method as claimed in any one of Claims 6 to 8,

wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

- 10. The method as claimed in any one of Claims 6 to 8, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.
- 11. A method for prognostic evaluation of carcinoma, which comprises
- (a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody,
- (b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and

10

15

25

- (c) a step of correlating the intensity of the specific antigen-antibody reaction with prognosis of carcinoma.
- 12. The method as claimed in Claim 11, wherein the carcinoma is gynecological carcinoma.
 - 13. The method as claimed in Claim 12, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.
- 20 14. The method as claimed in any one of Claims 11 to 13, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.
 - 15. The method as claimed in any one of Claims 11 to 13, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.
 - 16. An immunoassay kit for determination of the amount of P-LAP present in carcinoma tissues obtained from carcinoma patients, which comprises an anti-P-LAP antibody and a marker enzyme for determination of the amount of the P-LAP bound to

the anti-P-LAP antibody.